A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Clinical trial NCT06623422 · RECRUITING
Trial details
- NCT number
- NCT06623422
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-21
- Primary completion
- 2033-05-16
- Enrollment
- 680
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.